Search Results

The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.

Perfecting microbial manufacturing processes means taming its greatest asset: speed. This rapid process for creating biologics also means a race against time, where success hinges on conquering three key challenges: designing a robust microbial strain, optimizing fermentation for industrial scale, and ensuring consistent high-yield product yield.

Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.

Scorpion Biological Services announced it has changed its name to Scorpius BioManufacturing reflecting the company’s recently expanded manufacturing capabilities and the grand opening of its new biomanufacturing facility in San Antonio in October.

Recognized for Excellence in Drug Discovery Research Services on Global R&D Sourcing Platform in 2025.

Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation in an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST

With inspections always on the table, LOTTE Biologics is pushing a proactive, quality first culture across its dual hubs in Syracuse and Songdo, backing its new single‑use ADC facility with rigorous training, self‑audits and real‑time regulatory surveillance.

Scorpion Biological Services, a fully integrated contract research and contract development & manufacturing organization focused on the development of biologic drugs, hosted the grand opening of its new, state-of-the-art San Antonio facility on Friday, October 21, 2022.